Literature DB >> 7687730

Nitric oxide synthase activity in ulcerative colitis and Crohn's disease.

N K Boughton-Smith1, S M Evans, C J Hawkey, A T Cole, M Balsitis, B J Whittle, S Moncada.   

Abstract

Excessive nitric oxide (NO) production by an isoform of NO synthase that can be induced by inflammatory stimuli leads to changes in vascular permeability and to tissue injury. We measured NO synthase activities in mucosa and muscle from the colons of control patients (n = 11) and patients with ulcerative colitis (6) or Crohn's disease (4). NO synthase activity in colonic mucosa of ulcerative colitis patients was 0.55 (median interquartile range 0.32-0.57) nmol/min per g tissue, which was about eightfold higher than the value in control mucosa, with no individual overlap (p < 0.001). With colonic muscle there was no difference in NO synthase activity between ulcerative colitis patients and controls. In the patients with Crohn's disease, mucosal NO synthase activity did not differ from control values and activity in the colonic muscle was low. Thus, induction of colonic NO synthase may be involved in the mucosal vasodilation and increased vascular permeability of active ulcerative colitis, and could also contribute to the impaired motility that accompanies toxic dilation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687730     DOI: 10.1016/0140-6736(93)91476-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  96 in total

1.  Potentiation of cytokine induced iNOS expression in the human intestinal epithelial cell line, DLD-1, by cyclic AMP.

Authors:  M Cavicchi; B J Whittle
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

Review 2.  Peroxynitrite and inflammatory bowel disease.

Authors:  D M McCafferty
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

3.  New treatments for inflammatory bowel disease.

Authors:  David S Rampton; D Phil
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

4.  Heparin-Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine.

Authors:  Sufeng Zhang; Won Joon Cho; Amy T Jin; Lie Yun Kok; Yunhua Shi; David E Heller; Young-Ah Lucy Lee; Yixuan Zhou; Xi Xie; Joshua R Korzenik; Jochen K Lennerz; Giovanni Traverso
Journal:  Adv Healthc Mater       Date:  2020-06-29       Impact factor: 9.933

5.  Nitric oxide effect on colonocyte metabolism: co-action of sulfides and peroxide.

Authors:  W E Roediger; W J Babidge
Journal:  Mol Cell Biochem       Date:  2000-03       Impact factor: 3.396

6.  2-Amino-4-methylpyridine as a potent inhibitor of inducible NO synthase activity in vitro and in vivo.

Authors:  W S Faraci; A A Nagel; K A Verdries; L A Vincent; H Xu; L E Nichols; J M Labasi; E D Salter; E R Pettipher
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

7.  Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders.

Authors:  Tryggve Ljung; Sofie Lundberg; Mark Varsanyi; Catharina Johansson; Peter T Schmidt; Max Herulf; Jon O Lundberg; Per M Hellstrom
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

8.  Nitric oxide increases Wnt-induced secreted protein-1 (WISP-1/CCN4) expression and function in colitis.

Authors:  Hongying Wang; Rui Zhang; Shoubin Wen; Donna-Marie McCafferty; Paul L Beck; Wallace K MacNaughton
Journal:  J Mol Med (Berl)       Date:  2009-02-24       Impact factor: 4.599

Review 9.  Nitric oxide as a modulator of intestinal water and electrolyte transport.

Authors:  A A Izzo; N Mascolo; F Capasso
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

10.  Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease.

Authors:  D Rachmilewitz; J S Stamler; D Bachwich; F Karmeli; Z Ackerman; D K Podolsky
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.